Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRx closes offering, raises US$8.4mln

The cancer blood test firm issued 3.5mln shares at US$2.40 a share in the offering
VolitionRx closes offering, raises US$8.4mln
The group is focused on developing simple blood tests designed to help diagnose a range of cancers

Cancer testing firm VolitionRx Ltd (NYSE:VNRX) has raised US$8.4mln gross via its previously announced public offering, now closed.

It issued 3.5mln shares at US$2.40  a share.

"Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes," it said in the brief stock market statement Tuesday.

Oppenheimer & Co Inc. acted as the sole book-running manager.

Shares closed on Tuesday at US$2.34 each.

View full VNRX profile View Profile

VolitionRx Timeline

Related Articles

pipette and petri dish
Tue
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements
cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use